The drug regulator granted Priority Review and orphan drug designations for Onivyde. A study demonstrated the effectiveness of Onivyde. The three-arm, randomized, open label study involved as many as 417 patients with metastatic pancreatic adenocarcinoma whose cancer had grown after receiving the chemotherapeutic drug gemcitabine or a gemcitabine-based therapy.
Investigators found that patients treated with Onivyde plus fluorouracil/leucovorin lived an average of 6.1 months, compared to 4.2 months for those treated with only fluorouracil/leucovorin.
The safety of Onivyde was also tested in 398 patients who received either Onivyde with fluorouracil/leucovorin, Onivyde alone or fluorouracil/leucovorin. Merrimack Pharmaceuticals of Cambridge, Massachusetts holds the marketing authority of Onivyde.
Pancreatic Cancer - All About the Disease, its Diagnosis and Management
Pancreatic cancer often involves its exocrine part. It grows aggressively, and often detected late. Treatment options include surgery, radiation and chemotherapy.
Pancreatic cancer often involves its exocrine part. It grows aggressively, and often detected late. Treatment options include surgery, radiation and chemotherapy.
Source-Medindia
New Drug Combo Could Combat Pancreatic Cancer Better Than The Existing Drug
The combination of an experimental drug with an existing one reduced the viability of cancer cells by about 50 percent when compared with everolimus alone.
The combination of an experimental drug with an existing one reduced the viability of cancer cells by about 50 percent when compared with everolimus alone.
